Elicio Therapeutics, Inc. — Director's Dealing 2021

Feb 12, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Angion Biomedica Corp. (ANGN)
CIK: 0001601485
Period of Report: 2021-02-09

Reporting Person: Venkatesan Jay (Director, See Remarks)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-09	Common Stock	F	31966	$16	Disposed	1037017	Direct
2021-02-09	Common Stock	C	165094	—	Acquired	1202111	Direct
2021-02-09	Common Stock	X	237152	$6.43	Acquired	1439263	Direct
2021-02-09	Common Stock	S	159177	$16	Disposed	1208086	Direct
2021-02-09	Common Stock	C	262	$11.57	Acquired	1280348	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-09	Series C Cumulative Convertible Preferred	$	C	1804	Disposed		Common Stock (1804)	Direct
2021-02-09	Warrant to Purchase Common Stock	$6.43	X	237152	Disposed	2028-07-05	Common Stock (237152)	Direct
2021-02-09	Convertible Promissory Note	$16	C		Disposed		Common Stock ()	Direct

Footnotes

F1: The shares were withheld to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs").

F2: Includes 246,299 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof.

F3: Each share of the issuer's Series C Preferred Stock automatically converted into 91.52 shares of the issuer's Common Stock immediately prior to the consummation of the issuer's IPO and had no expiration date.

F4: On February 9, 2021 the Reporting Person exercised a warrant to purchase an aggregate of 396,328 shares of the Issuer's common stock for $16.00 a share, which represents the Issuer's IPO price. In connection with the automatic net exercise of the warrant immediately prior to the closing of the Issuer's IPO, the Issuer withheld 159,177 of the warrant shares to pay the exercise price and issued the remaining 237,152 shares of common stock to Reporting Person.

F5: The convertible promissory note converted immediately prior to the consummation of the IPO into Common Stock.

F6: The convertible promissory note ("Convertible Note") had a maturity date of August 14, 2021 and the principal amount of the Convertible Note converted upon the closing of the IPO into Common Shares at a conversion price equal to $18.00 per Common Share.